adenine has been researched along with B-Cell Leukemia in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examining phospho-Mer in leukemic blasts from mouse bone marrow." | 1.40 | UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. ( Cummings, CT; DeRyckere, D; Earp, HS; Frye, SV; Glaros, TG; Graham, DK; Hunter, D; Janzen, WP; Kireev, D; Lee, M; Liu, J; Minson, KA; Newton, DL; Sather, S; Stashko, MA; Wang, X; Zhang, D; Zhang, W, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Carda, JP | 1 |
| Santos, L | 1 |
| Mariz, JM | 1 |
| Monteiro, P | 1 |
| Gonçalves, HM | 1 |
| Raposo, J | 1 |
| Gomes da Silva, M | 1 |
| Göckeritz, E | 1 |
| Vondey, V | 1 |
| Guastafierro, A | 1 |
| Pizevska, M | 1 |
| Hassenrück, F | 1 |
| Neumann, L | 1 |
| Hallek, M | 2 |
| Krause, G | 1 |
| Zhang, Z | 1 |
| Zhang, D | 2 |
| Liu, Y | 1 |
| Yang, D | 1 |
| Ran, F | 1 |
| Wang, ML | 2 |
| Zhao, G | 1 |
| McCarter, SJ | 1 |
| Vijayvargiya, P | 1 |
| Sidana, S | 1 |
| Nault, AM | 1 |
| Lane, CE | 1 |
| Lehman, JS | 1 |
| Wilson, JW | 1 |
| Parikh, SA | 1 |
| Nowakowski, GS | 1 |
| Al-Kali, A | 1 |
| Wang, M | 1 |
| Xu, W | 1 |
| Li, JY | 1 |
| Zhang, W | 1 |
| DeRyckere, D | 1 |
| Hunter, D | 1 |
| Liu, J | 1 |
| Stashko, MA | 1 |
| Minson, KA | 1 |
| Cummings, CT | 1 |
| Lee, M | 1 |
| Glaros, TG | 1 |
| Newton, DL | 1 |
| Sather, S | 1 |
| Kireev, D | 1 |
| Janzen, WP | 1 |
| Earp, HS | 1 |
| Graham, DK | 1 |
| Frye, SV | 1 |
| Wang, X | 1 |
| Wang, Y | 1 |
| Zhang, LL | 1 |
| Champlin, RE | 1 |
| Jerkeman, M | 1 |
| Dreyling, M | 1 |
| Thieblemont, C | 1 |
| Kimby, E | 1 |
| Staudt, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2019-04-11 | Terminated (stopped due to Insufficient accrual) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib Plus Rituximab | 0 |
4 reviews available for adenine and B-Cell Leukemia
| Article | Year |
|---|---|
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Autoimmune Diseases; B | 2018 |
[Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chron | 2014 |
Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Drug Discovery; Humans | 2015 |
Targeting of B-cell receptor signalling in B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Humans | 2017 |
4 other studies available for adenine and B-Cell Leukemia
| Article | Year |
|---|---|
Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Disease Management; Humans; Leukemia, B-Cell; Patient | 2021 |
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Chemokines; Chem | 2017 |
A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses.
Topics: Abscess; Adenine; Antifungal Agents; Aspergillosis; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Orga | 2019 |
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
Topics: Adenine; Administration, Oral; Animals; Biological Availability; c-Mer Tyrosine Kinase; Cell Line, T | 2014 |